Biotechnology - ImmunoGen

Filter

Current filters:

ImmunoGen

Popular Filters

CytomX and ImmunoGen announce collaboration to develop Probody-Drug Conjugates against cancer targets

09-01-2014

US biotech firms CytomX Therapeutics and ImmunoGen (Nasdaq: IMGN) have signed a collaboration agreement…

BiotechnologyCytomX TherapeuticsImmunoGenLicensingOncologyResearchUSA

Immunogen quits small cell lung cancer study

05-11-2013

US biotech firm ImmunoGen (Nasdaq: IMGN) will stop the IMGN901 Phase II small cell lung cancer study,…

BiotechnologyImmunoGenNorth AmericaOncologyResearch

Novartis takes up license for ImmunoGen ADC technology

Novartis takes up license for ImmunoGen ADC technology

11-10-2013

US biotech firm ImmunoGen says that Swiss drug major Novartis has licensed the exclusive right to use…

BiotechnologyImmunoGenLicensingNovartisOncology

US FDA approves Roche's late-stage breast cancer drug Kadcyla

25-02-2013

The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead

20-12-2012

US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted…

AmgenArrowhead ResearchBiotechnologyImmunoGenLicensingOncologyPharmaceuticalRare diseasesShire

ImmunoGen IND for IMGN853 now active; IMGN529 trial commenced

17-04-2012

US biotechnology firm ImmunoGen (Nasdaq: IMGN) says that the Investigational New Drug (IND) application…

BiotechnologyImmunoGenOncologyResearch

Back to top